Cybin Inc Stock Price, News & Analysis

Cybin Inc. (AMEX:CYBN) has announced the publication of an international patent application by the World Intellectual Property Organization (WIPO) covering inhalation delivery methods for various psychedelic molecules. This PCT application strengthens Cybin’s intellectual property position, particularly for its CYB004 pipeline program utilizing deuterated DMT via inhalation. The patent allows the company to pursue applications for multiple inhaled forms of psychedelics, aligning with its strategy of creating improved treatment options for mental health disorders.

Cybin announces participation in the Benzinga Psychedelics Capital Conference on April 19, 2022. CEO Doug Drysdale will engage in a fireside chat at 1:10 p.m. ET and a panel discussion at 3:10 p.m. ET focused on catalysts in the psychedelics industry. The event will be streamed live, and recordings will be available on the company’s investor relations website. Founded in 2019, Cybin is a biopharmaceutical firm dedicated to creating effective therapeutics for mental health issues, operating in multiple countries including Canada and the U.S.

Cybin Inc. has announced that its subsidiary, Adelia Therapeutics, has met a milestone outlined in a previous transaction agreement. This achievement will lead to the issuance of 22,428.3 Class B common shares, representing approximately $228,769 to Adelia shareholders. The shares can be exchanged for Cybin's common shares at a specific ratio. CEO Doug Drysdale expressed satisfaction with the progress, indicating it supports clinical development for psychedelic-based therapies. The company aims to advance innovative drug delivery systems for mental health disorders.

Cybin Inc. (AMEX:CYBN) has initiated a feasibility study utilizing Kernel's Flow technology to objectively measure the effects of ketamine on brain activity during psychedelic experiences. This study is poised to gather quantitative data, a significant advancement compared to previous subjective reporting methods. Authorized by the FDA in October 2021, the study will involve participants receiving either low-dose ketamine or a placebo. Cybin retains exclusive rights to innovations resulting from the study, reinforcing its commitment to advancing psychedelic therapies.

Cybin Inc. has completed in vivo preclinical studies of its deuterated psilocybin analog CYB003 for treating major depressive disorder (MDD). The studies indicate CYB003 is well-tolerated and shows promising pharmacological properties, including a 50% reduction in dosage variability and faster onset compared to classic psilocybin. The Company plans to submit an IND to the FDA in Q2 2022 and initiate Phase 1/2a trials by mid-2022, aiming to advance CYB003 as a potential treatment for MDD and alcohol use disorder.

Cybin Inc. announced milestones achieved by its subsidiary, Adelia Therapeutics, in accordance with a Transaction Agreement dated December 4, 2020. As a result, 90,546 Class B common shares will be issued to Adelia shareholders, fulfilling an obligation of approximately $904,916.81. Each Class B Share is exchangeable for 10 Cybin Shares, starting December 14, 2021, with specific percentages unlockable in subsequent years. This transaction reflects Cybin's commitment to developing psychedelics for therapeutic use.

Cybin Inc. (AMEX:CYBN) has announced the recruitment for a feasibility study evaluating the effects of ketamine on participants using Kernel Flow's neuroimaging technology. Participants will experience either a low dose of ketamine or a placebo, while their brain activity is monitored. This groundbreaking research aims to quantify psychedelic experiences, potentially paving the way for larger studies that bridge psychedelics and therapeutics. CEO Doug Drysdale emphasized the study's significance in enhancing understanding of psychedelic effects on mental health.

Cybin, a biopharmaceutical company focused on mental health therapeutics, announced that CEO Doug Drysdale will present at the 2022 Virtual Growth Conference from March 28 to 30, 2022. The presentation will be available on demand starting March 28 at 9:00 a.m. ET. Interested attendees can register to access the conference and listen to the presentation via the company's website. Founded in 2019 and headquartered in Canada, Cybin is dedicated to advancing psychedelics for therapeutic use through innovative drug discovery and delivery systems.

Cybin Inc. (AMEX:CYBN) announced participation by CEO Doug Drysdale in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 8:40 a.m. ET. The event will highlight the company’s focus on transforming psychedelics into therapeutics for mental health issues. A webcast will be available for those interested in listening to the discussion. Cybin, operational in Canada, the US, UK, and Ireland, is committed to the development of innovative therapeutic solutions leveraging proprietary drug discovery platforms.